Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00898794
Recruitment Status : Unknown
Verified June 2011 by National Cancer Institute (NCI).
Recruitment status was:  Recruiting
First Posted : May 12, 2009
Last Update Posted : August 7, 2013
Sponsor:
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about the effect of bevacizumab and VEGF on platelet clustering.

PURPOSE: This research study is looking at the effect of bevacizumab and VEGF on platelet clustering in patients with cancer who are receiving bevacizumab.


Condition or disease Intervention/treatment
Unspecified Adult Solid Tumor, Protocol Specific Unspecified Childhood Solid Tumor, Protocol Specific Biological: bevacizumab Other: coagulation study Other: laboratory biomarker analysis Other: platelet aggregation test

Detailed Description:

OBJECTIVES:

  • To determine the influence of bevacizumab on platelet aggregation in patients receiving bevacizumab for cancer.
  • To determine the influence of VEGF on platelet aggregation.
  • To determine the influence of VEGF or bevacizumab on cyclooxygenesis.
  • To determine if the sequence of medication plays a role in platelet aggregation.

OUTLINE: Blood samples are collected before and after bevacizumab infusion. Samples are analyzed for measurements of platelet aggregation, coagulation parameters, and endothelial activation (e.g., fibrin fragment F1 and 2, thrombin and antithrombin complex, soluble P-selectin, Von Willebrand factor and factor VIII, tissue factor, and endothelin 1).

Layout table for study information
Study Type : Observational
Estimated Enrollment : 20 participants
Official Title: Influence of Bevacizumab and VEGF on Platelet Aggregation
Study Start Date : October 2007
Estimated Primary Completion Date : May 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab




Primary Outcome Measures :
  1. Influence of bevacizumab on platelet aggregation
  2. Influence of VEGF on platelet aggregation
  3. Influence of VEGF or bevacizumab on cyclooxygenesis
  4. Correlation between medication sequence and platelet aggregation


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Receiving bevacizumab for cancer

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00898794


Locations
Layout table for location information
Switzerland
Kantonsspital Graubuenden Recruiting
Chur, Switzerland, CH-7000
Contact: Roger von Moos, MD    41-81-256-6646    roger.vonmoos@ksgr.ch   
Sponsors and Collaborators
Kantonsspital Graubuenden
Investigators
Layout table for investigator information
Principal Investigator: Roger von Moos, MD Kantonsspital Graubuenden
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00898794    
Other Study ID Numbers: KSGR-GR-01-07
CDR0000631252 ( Registry Identifier: PDQ (Physician Data Query) )
First Posted: May 12, 2009    Key Record Dates
Last Update Posted: August 7, 2013
Last Verified: June 2011
Keywords provided by National Cancer Institute (NCI):
unspecified adult solid tumor, protocol specific
unspecified childhood solid tumor, protocol specific
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Bevacizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors